Collegium Pharm Inc Drug Patent Portfolio
Collegium Pharm Inc owns 3 orange book drugs protected by 32 US patents Given below is the list of Collegium Pharm Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10188644 | Process of making stable abuse-deterrent oral formulations | 02 Sep, 2036 | Active |
| US10646485 | Process of making stable abuse-deterrent oral formulations | 02 Sep, 2036 | Active |
| US9737530 | Process of making stable abuse-deterrent oral formulations | 02 Sep, 2036 | Active |
| US9968598 | Process of making stable abuse-deterrent oral formulations | 02 Sep, 2036 | Active |
| US10004729 | Tamper-resistant pharmaceutical compositions of opioids and other drugs | 10 Dec, 2030 | Active |
| US10668060 | Tamper-resistant pharmaceutical compositions of opioids and other drugs | 10 Dec, 2030 | Active |
| US9682075 | Tamper-resistant pharmaceutical compositions of opioids and other drugs | 10 Dec, 2030 | Active |
| US8536130 | Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain | 22 Mar, 2029 | Active |
| US11344512 | Titration of tapentadol | 21 Oct, 2028 | Active |
| US8536130 | Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain | 22 Sep, 2028 | Active |
| US11344512 | Titration of tapentadol | 21 Apr, 2028 | Active |
| US7994364 | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride | 27 Dec, 2025 | Active |
| US7994364 | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride | 27 Jun, 2025 | Active |
| US8758813 | Abuse-deterrent drug formulations | 10 Jun, 2025 | Active |
| US7399488 | Abuse-deterrent pharmaceutical compositions of opiods and other drugs | 24 Mar, 2025 | Expired |
| US7771707 | Abuse-deterrent drug formulations | 24 Mar, 2025 | Expired |
| US8449909 | Abuse-deterrent drug formulations | 24 Mar, 2025 | Expired |
| US8557291 | Abuse-deterrent pharmaceutical compositions of opioids and other drugs | 21 Mar, 2025 | Expired |
| US8114383 | Abuse-proofed dosage form | 10 Oct, 2024 | Expired |
| US8075872 | Abuse-proofed dosage form | 20 Nov, 2023 | Expired |
| US8309060 | Abuse-proofed dosage form | 20 Nov, 2023 | Expired |
| US8420056 | Abuse-proofed dosage form | 20 Nov, 2023 | Expired |
| US10525052 | Abuse-deterrent drug formulations | 07 Jul, 2023 | Expired |
| US10525053 | Abuse-deterrent pharmaceutical compositions of opioids and other drugs | 07 Jul, 2023 | Expired |
| US8840928 | Tamper-resistant pharmaceutical compositions of opioids and other drugs | 07 Jul, 2023 | Expired |
| US9044398 | Abuse-deterrent pharmaceutical compositions of opiods and other drugs | 07 Jul, 2023 | Expired |
| US9248195 | Abuse-deterrent pharmaceutical compositions of opioids and other drugs | 07 Jul, 2023 | Expired |
| US9592200 | Abuse-deterrent pharmaceutical compositions of opioids and other drugs | 07 Jul, 2023 | Expired |
| US9763883 | Abuse-deterrent drug formulations | 07 Jul, 2023 | Expired |
| US11007156 | Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol | 22 Oct, 2022 | Expired |
| USRE39593 | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects | 05 Aug, 2022 | Expired |
| US6071970 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | 06 Jun, 2017 | Expired |
Latest Legal Activities on Collegium Pharm Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Collegium Pharm Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Maintenance Fee Reminder Mailed
Critical
| 01 Jul, 2024 | US8309060 |
| Second letter to regulating agency to determine regulatory review period | 20 Mar, 2024 | US7771707 |
| Second letter to regulating agency to determine regulatory review period | 20 Mar, 2024 | US8449909 |
| Requirement for information sent under 37 CFR 1.750 | 20 Mar, 2024 | US7771707 |
| Second letter to regulating agency to determine regulatory review period | 20 Mar, 2024 | US7399488 |
|
Expire Patent
Critical
| 12 Feb, 2024 | US10525053 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 15 Nov, 2023 | US10668060 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 25 Oct, 2023 | US10646485 |
| Letter from FDA or Dept of Agriculture re PTE application | 19 Oct, 2023 | US7771707 |
| Letter from FDA or Dept of Agriculture re PTE application | 19 Oct, 2023 | US7399488 |
|
Maintenance Fee Reminder Mailed
Critical
| 28 Aug, 2023 | US10525053 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 02 Aug, 2023 | US8114383 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 21 Jun, 2023 | US10525052 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 31 May, 2023 | US8075872 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 25 Jan, 2023 | US7994364 (Litigated) |
Collegium Pharm Inc's Drug Patent Litigations
Collegium Pharm Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 15, 2016, against patent number US7994364. The petitioner Rosellini Scientific, LLC, challenged the validity of this patent, with Gruenenthal GmbH as the respondent. Click below to track the latest information on how companies are challenging Collegium Pharm Inc's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7994364 | January, 2016 |
Terminated-Denied
(18 Jul, 2016)
| Gruenenthal GmbH | Rosellini Scientific, LLC |
Collegium Pharm Inc Drug Patents' Oppositions Filed in EPO
Collegium Pharm Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 14, 2007, by Purdue Pharma Lp. This opposition was filed on patent number EP04763834A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP06706682A | Dec, 2017 | G. L. Pharma GmbH | Revoked |
| EP08749016A | Aug, 2012 | Generics [UK] Limited | Revoked |
| EP2005006983W | Oct, 2009 | Sanofi-Aventis Deutschland GmbH | Patent maintained as amended |
| EP2005006983W | Oct, 2009 | Ypsomed AG | Patent maintained as amended |
| EP04763833A | Mar, 2008 | Purdue Pharma LP | Opposition rejected |
| EP04763834A | Dec, 2007 | Purdue Pharma LP | Opposition rejected |
Collegium Pharm Inc's Family Patents
Collegium Pharm Inc drugs have patent protection in a total of 33 countries. It's US patent count contributes only to 31.5% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Collegium Pharm Inc Drug List
Given below is the complete list of Collegium Pharm Inc's drugs and the patents protecting them.
1. Nucynta
Nucynta is protected by 4 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7994364
(Pediatric)
| Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
27 Dec, 2025
(7 months from now)
| Active |
| US7994364 | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
27 Jun, 2025
(a month from now)
| Active |
| USRE39593 | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects |
05 Aug, 2022
(2 years ago)
| Expired |
| US6071970 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
06 Jun, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nucynta's drug page
2. Nucynta Er
Nucynta Er is protected by 13 patents, out of which 7 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8536130
(Pediatric)
| Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain |
22 Mar, 2029
(3 years from now)
| Active |
| US11344512
(Pediatric)
| Titration of tapentadol |
21 Oct, 2028
(3 years from now)
| Active |
| US8536130 | Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain |
22 Sep, 2028
(3 years from now)
| Active |
| US11344512 | Titration of tapentadol |
21 Apr, 2028
(2 years from now)
| Active |
| US7994364
(Pediatric)
| Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
27 Dec, 2025
(7 months from now)
| Active |
| US7994364 | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
27 Jun, 2025
(a month from now)
| Active |
| US8114383 | Abuse-proofed dosage form |
10 Oct, 2024
(6 months ago)
| Expired |
| US8075872 | Abuse-proofed dosage form |
20 Nov, 2023
(1 year, 5 months ago)
| Expired |
| US8309060 | Abuse-proofed dosage form |
20 Nov, 2023
(1 year, 5 months ago)
| Expired |
| US8420056 | Abuse-proofed dosage form |
20 Nov, 2023
(1 year, 5 months ago)
| Expired |
| US11007156 | Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol |
22 Oct, 2022
(2 years ago)
| Expired |
| USRE39593 | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects |
05 Aug, 2022
(2 years ago)
| Expired |
| US6071970 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
06 Jun, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nucynta Er's drug page
3. Xtampza Er
Xtampza Er is protected by 19 patents, out of which 11 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10188644 | Process of making stable abuse-deterrent oral formulations |
02 Sep, 2036
(11 years from now)
| Active |
| US10646485 | Process of making stable abuse-deterrent oral formulations |
02 Sep, 2036
(11 years from now)
| Active |
| US9737530 | Process of making stable abuse-deterrent oral formulations |
02 Sep, 2036
(11 years from now)
| Active |
| US9968598 | Process of making stable abuse-deterrent oral formulations |
02 Sep, 2036
(11 years from now)
| Active |
| US10004729 | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
10 Dec, 2030
(5 years from now)
| Active |
| US10668060 | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
10 Dec, 2030
(5 years from now)
| Active |
| US9682075 | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
10 Dec, 2030
(5 years from now)
| Active |
| US8758813 | Abuse-deterrent drug formulations |
10 Jun, 2025
(29 days from now)
| Active |
| US7399488 | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
24 Mar, 2025
(a month ago)
| Expired |
| US7771707 | Abuse-deterrent drug formulations |
24 Mar, 2025
(a month ago)
| Expired |
| US8449909 | Abuse-deterrent drug formulations |
24 Mar, 2025
(a month ago)
| Expired |
| US8557291 | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
21 Mar, 2025
(a month ago)
| Expired |
| US10525052 | Abuse-deterrent drug formulations |
07 Jul, 2023
(1 year, 10 months ago)
| Expired |
| US10525053 | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
07 Jul, 2023
(1 year, 10 months ago)
| Expired |
| US8840928 | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
07 Jul, 2023
(1 year, 10 months ago)
| Expired |
| US9044398 | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
07 Jul, 2023
(1 year, 10 months ago)
| Expired |
| US9248195 | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
07 Jul, 2023
(1 year, 10 months ago)
| Expired |
| US9592200 | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
07 Jul, 2023
(1 year, 10 months ago)
| Expired |
| US9763883 | Abuse-deterrent drug formulations |
07 Jul, 2023
(1 year, 10 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xtampza Er's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List